Ep. 358 - Europe's biotech challenge

April 1, 2026·24 min·1 clip

How can European biotech compete when speed to clinical data is the new global currency?

1. BioCentury This Week's special edition, hosted by Jeff with Simone Fishburne and Stephen Hansen, examines European biotech competitiveness ahead of the 26th BioEquity Europe conference in Prague, May 4-6. 2. Guests include Petra Kinslova, CEO of Prague Bio, and Christoph Broda of EQT Life Sciences; Simone Fishburne is BioCentury editor-in-chief and Stephen Hansen is BioCentury's UK correspondent. 3. The episode's central thesis is that China's ability to generate early clinical data rapidly has reset global expectations for speed, and European biotech must respond structurally or lose investment and trial activity. 4. Simone Fishburne frames China's competitive pressure as a data-generation speed advantage that forces European companies, investors, and regulators to prioritize the clinical trial timeline from study start to early human proof-of-concept. 5. BioCentury's scene-setter for BioEquity Europe will analyze European clinical trial competitiveness by therapeutic area concentration, recruitment rates, and country-level over-indexing relative to population—data still being finalized by colleague Lindsey Martin. 6. Petra Kinslova describes Prague and Brno as the Czech Republic's two main biotech hubs: Prague is strong in medicinal chemistry and early drug discovery, anchored by the IOCB (Institute of Organic Chemistry and Biochemistry), which generated major antiviral drug royalties under Professor Antonín Holý's HIV and hepatitis research. 7. The IOCB's success seeded a technology transfer ecosystem including IOCB Tech and a Boston branch; BioCentury's conference program includes panelist Tomáš Cihlář of Gilead Sciences, who connects directly to the Holly antiviral drug lineage. 8. Stephen Hansen explains the European Life Sciences Coalition, launched in February, which is pushing two parallel reforms: increasing institutional capital flows to European biotech venture funds, and improving clinical trial competitiveness. 9. Hansen cites the coalition's key statistic: European pension funds allocate just 0.02% of assets to venture capital, versus 2% for US pension funds—a gap he attributes to a deeply ingrained mandate to preserve capital that has persisted since US pension funds made their own shift in the 1970s. 10. The coalition is working with the European Investment Bank to develop fund-of-funds vehicles that would give pension funds cost-efficient access to venture exposure without requiring them to build direct investment teams. 11. Christoph Broda states that where to run clinical trials is now a board-level question at EQT portfolio companies, with cell therapy and CAR T cited as areas where Chinese biotechs have demonstrated a concrete playbook for faster, cheaper data generation. 12. Broda identifies ethics committee fragmentation as a primary structural barrier: European multi-country trials require separate ethics body approvals in each country, unlike the US, where IRB approval can cross state lines, or China, which has centralized approvals. 13. The EU Biotech Act, proposed in December, aims to simplify and shorten end-to-end multinational trial authorization timelines, with a potential 47-day target, though Broda notes it is unclear whether this is comparable to the US FDA's 30-day CTA response clock. 14. Jeff describes the UK's MHRA, under CEO Lawrence Tallon, as taking aggressive concrete steps including a 14-day turnaround commitment and a single-contracting system across NHS hospitals, positioning the UK as a potential model for European reform. 15. Simone raises the Mansion House Compact and Robert Maxwell's historical role in shaping UK pension fund risk aversion as context for why opening UK pension funds to biotech investment is a slow, culturally embedded change. 16. Broda argues that more capital availability is itself a risk management tool in biotech: larger capital pools allow companies to build diversified pipelines instead of binary single-asset stories, reducing the specific risk that makes pension funds averse. 17. Jeff identifies drug pricing as the structural overhang that ultimately limits European biotech attractiveness: even European-headquartered pharma companies are pushing back on EU pricing frameworks, and the US MFN pressure may create a window for Europe to differentiate. 18. Broda agrees that the US has historically subsidized global drug innovation by accepting high drug prices, and argues Europe must better articulate the societal value of medicines to create a more favorable commercial environment. 19. Biotech investors, policy advocates, and clinical operations executives focused on European market development will find this episode directly relevant to ongoing regulatory and capital market debates. 20. Listeners seeking company-specific investment analysis or clinical data updates will find this episode too high-level and policy-focused.

As heard by us

European biotech is cast as a contest over speed, capital, and policy.

The piece frames European biotech as a race toward the clinic: faster early human data, faster de-risking, and a clearer path to investment and partnering.

Read the full review in PlayNext →

Why you'd press play

You want the European biotech playbook before BioEquity Prague.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from BioCentury This Week